Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma
出版年份 2018 全文链接
标题
Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma
作者
关键词
-
出版物
Frontiers in Pharmacology
Volume 9, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2018-10-01
DOI
10.3389/fphar.2018.01118
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Vitamin D receptor gene methylation in hepatocellular carcinoma
- (2018) Mai Abdalla et al. GENE
- Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma
- (2018) Min Yu et al. MOLECULAR THERAPY
- CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges
- (2018) Stephen J Bagley et al. NEURO-ONCOLOGY
- CAR T cell immunotherapy for human cancer
- (2018) Carl H. June et al. SCIENCE
- CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial
- (2018) Yao Wang et al. OncoImmunology
- Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity
- (2017) Wenpeng Li et al. HUMAN GENE THERAPY
- Progress and prospects of circular RNAs in Hepatocellular carcinoma: Novel insights into their function
- (2017) Ji Hu et al. JOURNAL OF CELLULAR PHYSIOLOGY
- LncRNA GHET1 predicts poor prognosis in hepatocellular carcinoma and promotes cell proliferation by silencing KLF2
- (2017) Li Jin et al. JOURNAL OF CELLULAR PHYSIOLOGY
- A Fusion Receptor as a Safety Switch, Detection, and Purification Biomarker for Adoptive Transferred T Cells
- (2017) Xiuqi Wu et al. MOLECULAR THERAPY
- Treatment of hepatocellular carcinoma with a GPC3-targeted bispecific T cell engager
- (2017) Yanyu Bi et al. Oncotarget
- CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells
- (2017) Levi J. Rupp et al. Scientific Reports
- Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma
- (2017) Zhiwu Jiang et al. Frontiers in Immunology
- Galectin 3 as a guardian of the tumor microenvironment
- (2016) Peter P. Ruvolo BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Tumor-associated GM-CSF overexpression induces immunoinhibitory molecules via STAT3 in myeloid-suppressor cells infiltrating liver metastases
- (2016) M Thorn et al. CANCER GENE THERAPY
- Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma
- (2016) Cheng Chen et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- TALEN-Mediated Inactivation of PD-1 in Tumor-Reactive Lymphocytes Promotes Intratumoral T-cell Persistence and Rejection of Established Tumors
- (2016) Laurie Menger et al. CANCER RESEARCH
- Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition
- (2016) Jiangtao Ren et al. CLINICAL CANCER RESEARCH
- Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
- (2016) Leonid Cherkassky et al. JOURNAL OF CLINICAL INVESTIGATION
- GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade
- (2016) Tessa Gargett et al. MOLECULAR THERAPY
- Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
- (2016) Vassiliki A. Boussiotis NEW ENGLAND JOURNAL OF MEDICINE
- Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects
- (2016) Shengmeng Di et al. Science China-Life Sciences
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation
- (2016) Kankana Bardhan et al. Frontiers in Immunology
- Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer
- (2016) Ruea-Yea Huang et al. OncoImmunology
- PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma
- (2016) Chang-Long Chen et al. OncoImmunology
- Emerging role of cystic fibrosis transmembrane conductance regulator - an epithelial chloride channel in gastrointestinal cancers
- (2016) Yuning Hou et al. World Journal of Gastrointestinal Oncology
- CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients
- (2016) Shu Su et al. Scientific Reports
- Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells
- (2015) Zeguo Zhao et al. CANCER CELL
- Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
- (2015) Scott N. Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- T cell exclusion, immune privilege, and the tumor microenvironment
- (2015) J. A. Joyce et al. SCIENCE
- Adoptive cellular therapy: A race to the finish line
- (2015) Carl H. June et al. Science Translational Medicine
- Identification of an Exon 4-Deletion Variant of Epidermal Growth Factor Receptor with Increased Metastasis-Promoting Capacity
- (2015) Hai Wang et al. NEOPLASIA
- ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells
- (2014) S. Guedan et al. BLOOD
- Generation of Gene-Modified Cynomolgus Monkey via Cas9/RNA-Mediated Gene Targeting in One-Cell Embryos
- (2014) Yuyu Niu et al. CELL
- Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular Carcinoma
- (2014) H. Gao et al. CLINICAL CANCER RESEARCH
- Immunologic and Clinical Effects of Targeting PD-1 in Lung Cancer
- (2014) R D Harvey CLINICAL PHARMACOLOGY & THERAPEUTICS
- Dual sgRNAs facilitate CRISPR/Cas9-mediated mouse genome targeting
- (2014) Jiankui Zhou et al. FEBS Journal
- Hepatic Immune Regulation and Its Involvement in Viral Hepatitis Infection
- (2014) Percy A. Knolle et al. GASTROENTEROLOGY
- Cabozantinib reverses multidrug resistance of human hepatoma HepG2/adr cells by modulating the function of P-glycoprotein
- (2014) Qing-feng Xiang et al. LIVER INTERNATIONAL
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Easy quantitative assessment of genome editing by sequence trace decomposition
- (2014) Eva K. Brinkman et al. NUCLEIC ACIDS RESEARCH
- Multiplex Genome Engineering Using CRISPR/Cas Systems
- (2013) L. Cong et al. SCIENCE
- Role of microRNAs in hepatocellular carcinoma: a clinical perspective
- (2013) Massimo Negrini et al. OncoTargets and Therapy
- Beyond the Antigen Receptor: Editing the Genome of T-Cells for Cancer Adoptive Cellular Therapies
- (2013) Angharad Lloyd et al. Frontiers in Immunology
- Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma
- (2011) C. U. Louis et al. BLOOD
- Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen
- (2009) L. A. Johnson et al. BLOOD
- Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI3kinase/AKT/Bcl-XL Activation and CD8+ T Cell–mediated Tumor Eradication
- (2009) Xiao-Song Zhong et al. MOLECULAR THERAPY
- Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains
- (2009) C. Carpenito et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started